Can a blood test tell who will respond to lung cancer immunotherapy?

NCT ID NCT07608835

Recruiting now Knowledge-focused Sponsor: Institut Paoli-Calmettes Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is collecting blood and tumor samples from 200 people with non-small cell lung cancer to find biological markers that predict whether immunotherapy will work. Researchers will compare samples taken before treatment and at the time the disease gets worse. The goal is to better understand why only about 40% of patients respond to current immunotherapies and to identify new targets for treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which lung cancer patients will benefit from immunotherapy and point toward new treatment targets.
What could go wrong: This is an observational study, not a treatment trial. It may not lead directly to new therapies, and the findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Rochigneux
RECRUITING

Marseille, Institut Paoli Calmettes, 13009, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.